Cardiac contractility modulation with the impulse dynamics signal: studies in dogs with chronic heart failure

H N Sabbah1, W Haddad, Y Mika

  • 1Department of Medicine & Division of Cardiovascular Medicine, Henry Ford Heart & Vascular Institute, Detroit, Michigan USA. hsabbahl@hfhs.org

Heart Failure Reviews
|March 15, 2001
PubMed

Insights

Cardiac contractility modulation (CCM) offers a novel, non-pharmacologic approach to support failing hearts. This electrical signal therapy shows promise for improving heart function without the risks of traditional inotropic agents.

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Heart Failure Research

Background:

  • Positive inotropic agents for heart failure (HF) have limitations including pro-arrhythmic and positive chronotropic effects.
  • Chronic use of existing inotropic agents increases mortality in advanced HF patients.
  • Need for safe and effective on-demand positive inotropic support for advanced HF.

Purpose of the Study:

  • To examine a novel, non-stimulatory electrical signal for modulating left ventricular (LV) contractility.
  • To assess the efficacy of Cardiac Contractility Modulation (CCM) for acute positive inotropic support in a canine HF model.

Main Methods:

  • Chronic heart failure induced in dogs via intracoronary microembolizations.
  • Delivery of the CCM signal (Impulse Dynamics) via a lead in the great coronary vein.
  • Assessment of hemodynamic parameters (cardiac output, LV peak+dP/dt, LV fractional shortening, LV ejection fraction) and cardiomyocyte function.

Main Results:

  • Acute CCM signal delivery significantly improved cardiac output and LV contractility parameters.
  • Functional improvements returned to baseline upon signal discontinuation.
  • CCM application improved isolated cardiomyocyte shortening and calcium transient dynamics.

Conclusions:

  • Pre-clinical results suggest CCM is a non-pharmacologic modality for short-term positive inotropic support in heart failure.
  • CCM may serve as a useful adjunct therapy for advanced heart failure.
  • Further long-term studies are required to establish chronic safety and efficacy.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...